Key facts
- It has raised $8.4M.
- Notable investors include National Institutes of Health, New York Ventures, Cornell University, Jefferson Life Sciences, National Institutes of Arthritis and Musculoskeletal Diseases.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Fesarius Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Fesarius Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fesarius Therapeutics
Developer of bioregenerative medical technologies designed to advance wound care, reconstructive surgery, and regenerative medicine. The company offers patented differential density hydrogel dermal matrices, including FDA-cleared DermiSphere, enabling healthcare providers to address diverse indications in plastics, pelvic health, orthopedics, and aesthetics with innovative and effective solutions.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2015
- Employees
- 6
- Website
- fesariustherapeutics.com/
- Ownership
- Privately Held (backing)
Fesarius Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fesarius Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fesarius Therapeutics in its N-PORT filings yet. We sweep new filings monthly.